K-Ras(G12C) inhibitor 9

Cat. No.: HY-12446: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

K-Ras (G12C) inhibitor 9 is an allosteric inhibitor of the K-Ras (G12C).

For research use only. We do not sell to patients.

K-Ras(G12C) inhibitor 9 Chemical Structure

CAS No. : 1469337-91-4

Size	Price	Stock	Quantity
2 mg	USD 163	Get quote 3 - 4 weeks 2 - 3 weeks 2 - 3 weeks	Estimated Time of Arrival: December 31
5 mg		Get quote
10 mg		Get quote

Synthetic products have potential research and development risk.

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Ras Isoform Specific Products:

View All Isoforms

K-Ras H-Ras N-Ras Ras

Biological Activity
Purity & Documentation
References
Customer Review

Description

K-Ras (G12C) inhibitor 9 is an allosteric inhibitor of the K-Ras (G12C)^[1].

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	5.2 μM Compound: SH-9	Antiproliferative activity against human A549 cells harboring KRAS G12S mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human A549 cells harboring KRAS G12S mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 36228411]
MRC5	IC₅₀	10.3 μM Compound: SH-9	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 36228411]
NCI-H2228	IC₅₀	7.2 μM Compound: SH-9	Antiproliferative activity against human NCI-H2228 cells harboring wild type KRAS assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H2228 cells harboring wild type KRAS assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 36228411]
NCI-H23	IC₅₀	3 μM Compound: SH-9	Antiproliferative activity against human NCI-H23 cells harboring KRAS G12C mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H23 cells harboring KRAS G12C mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 36228411]
NCI-H358	IC₅₀	4.4 μM Compound: SH-9	Antiproliferative activity against human NCI-H358 cells harboring KRAS G12C mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H358 cells harboring KRAS G12C mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 36228411]
NCI-H441	IC₅₀	21.5 μM Compound: SH-9	Antiproliferative activity against human NCI-H441 cells harboring KRAS G12V mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human NCI-H441 cells harboring KRAS G12V mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 36228411]
SK-LU-1	IC₅₀	22.8 μM Compound: SH-9	Antiproliferative activity against human SK-LU-1 cells harboring KRAS G12D mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay Antiproliferative activity against human SK-LU-1 cells harboring KRAS G12D mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 36228411]

Molecular Weight

513.78

Formula

C₁₆H₂₁ClIN₃O₄S

CAS No.

1469337-91-4

Appearance

Solid

Color

White to off-white

SMILES

C=CS(=O)(NC1CCN(C(CNC2=CC(I)=C(Cl)C=C2OC)=O)CC1)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Purity & Documentation

Purity: ≥98.0%

Select Batch:

Data Sheet (265 KB) SDS (393 KB)

COA (246 KB)

Handling Instructions (2659 KB)

References

[1]. Ostrem JM, et al. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013 Nov 28;503(7477):548-51. [Content Brief]